<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00342381</url>
  </required_header>
  <id_info>
    <org_study_id>20060003</org_study_id>
    <nct_id>NCT00342381</nct_id>
  </id_info>
  <brief_title>Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation</brief_title>
  <official_title>Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate fatigue in patients with multiple sclerosis (MS)
      and to determine the correlation between the symptom and cerebral changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only recruiting from:

      Department of Neurology, Aarhus University Hospital, Denmark
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective fatigue (FSS)</measure>
    <time_frame>Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal voluntary isometric contraction, central activation before and after exercise</measure>
    <time_frame>at the time of investigation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Symbol-Coding scores</measure>
    <time_frame>Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in normal appearing white matter and normal appearing gray matter (MRS-, MTI- and DTI- parameters)</measure>
    <time_frame>at the time of MRI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortical atrophy</measure>
    <time_frame>at the time of MRI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intracortical inhibition/facilitation determined by transcranial magnetic stimulation (+/- 3,4-diaminopyridine)</measure>
    <time_frame>at the time of investigation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective fatigue (MFI-20, Danish version)</measure>
    <time_frame>Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid voluntary twitches</measure>
    <time_frame>at the time of investigation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>at the time of investigation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-hole peg test</measure>
    <time_frame>at the time of investigation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WAIS/WMS tests</measure>
    <time_frame>at the time of investigation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO-5 Questionnaire</measure>
    <time_frame>at the time of investigation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory</measure>
    <time_frame>at the time of investigation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion load</measure>
    <time_frame>at the time of MRI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain atrophy</measure>
    <time_frame>at the time of MRI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective fatigue (VAS)</measure>
    <time_frame>at the time of investigation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>3.4 diaminopyridine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 3,4 diaminopyridine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets identical to active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-diaminopyridine</intervention_name>
    <description>Single dose 3,4 diaminopyridine</description>
    <arm_group_label>3.4 diaminopyridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose placebo treatment</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>n/d</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing remitting-multiple sclerosis (RR-MS) according to Poser criteria

          -  EDSS: max 3.5

          -  Right handed

          -  Normal function of the right hand

        Exclusion Criteria:

          -  Disease interfering with MS

          -  Known dementia

          -  Drug or alcohol abuse

          -  Treatment with psychoactive drugs within one week before study entry

          -  Major changes of medical treatment within 3 weeks before study entry

          -  Attack within 4 weeks before study entry

          -  Pregnancy

          -  Conditions interfering with 3,4-diaminopyridine treatment

          -  Conditions interfering with MRI

          -  Conditions interfering with transcranial magnetic stimulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Andersen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Aarhus Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Jacobsen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Neurology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2006</study_first_submitted>
  <study_first_submitted_qc>June 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <last_update_submitted>December 12, 2007</last_update_submitted>
  <last_update_submitted_qc>December 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2007</last_update_posted>
  <responsible_party>
    <name_title>Henning Andersen</name_title>
    <organization>Dep of neurology, Aarhus University Hospital</organization>
  </responsible_party>
  <keyword>Motor fatigue</keyword>
  <keyword>Cognitive fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,4-diaminopyridine</mesh_term>
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

